145474-13-1

Upstream product

• 145474-07-3 methyl 7-[1-(methoxycarbonyl)propyl]-5-oxo-1,2,3,5-tetrahydroindolizine-8-carboxylate 
• 145474-06-2 methyl 7-methoxycarbonylmethyl-5-oxo-1,2,3,5-tetrahydroindolizine-8-carboxylate 
• 36625-47-5 methyl α-(tetrahydro-2-pyrrolidinylidene)acetate 
• 120461-65-6 dimethyl 3-chloro-2-pentenedioate 
• 100-52-7 benzaldehyde 
• 145474-08-4 4-ethyl-3,10-dioxo-1H,3H,4H,6H,7H,8H,10H-pyrano[3,4-f]indolizine-5-carboxylic acid methyl ester 

Downstream Products

• 86639-52-3 7-ethyl-10-hydroxycamptothecin 
• 110351-94-5 (4S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione 
• 7689-03-4 camptothecin 
• 31456-25-4 camptothecin 
• 64439-81-2 dl-10-hydroxycamptothecin 
• 130144-34-2 4,11-diethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione 

Relevant academic research and scientific papers

An improved synthesis of (20S)-camptothecin and its analogue via an asymmetric α-hydroxylation with a chiral organocatalyst

An efficient and stereocontrolled synthesis of (20S)-camptothecin and an analogue has been developed. The key feature of this synthesis is the organocatalyzed asymmetric α-hydroxylation of the lactone precursor 4 to construct its stereocenter, providing tricyclic hydroxylactone 2 in 90% yield and with 88% enantioselectivity. The precursor 4 was efficiently synthesized from the known pyridine 5 in three steps.

Concise Total Syntheses of dl-Camptothecin and Related Anticancer Drugs

The readily available tricyclic ester 10 has been converted to dl-camptothecin (1) in 39percent yield.It was discovered that, with the C5 carbomethoxy group in place, the C6 benzylic position of 10 (pyridone numbering) is selectively